Breaching the Blood–Brain Tumor Barrier for Tumor Therapy

SIMPLE SUMMARY: The blood–brain tumor barrier (BBTB) represents a major obstacle for the delivery of anticancer drugs to tumors of the central nervous system. Various approaches have been so far developed for overcoming this obstacle and for increasing anti-cancer drug concentrations in tumor tissues. This review is focused on the latest clinical advances and achievements in breaching the BBTB for primary and secondary brain tumor therapy. ABSTRACT: Tumors affecting the central nervous system (CNS), either primary or secondary, are highly prevalent and represent an unmet medical need. Prognosis of these tumors remains poor, mostly due to the low intrinsic chemo/radio-sensitivity of tumor cells, a meagerly known role of the microenvironment and the poor CNS bioavailability of most used anti-cancer agents. The BBTB is the main obstacle for anticancer drugs to achieve therapeutic concentrations in the tumor tissues. During the last decades, many efforts have been devoted to the identification of modalities allowing to increase drug delivery into brain tumors. Until recently, success has been modest, as few of these approaches reached clinical testing and even less gained regulatory approval. In recent years, the scenario has changed, as various conjugates and drug delivery technologies have advanced into clinical testing, with encouraging results and without being burdened by a heavy adverse event profile. In this article, we review the different approaches aimed at increasing drug delivery to brain tumors, with particular attention to new, promising approaches that increase the permeability of the BBTB or exploit physiological transport mechanisms.